- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00369655
VEGF Trap in Treating Patients With Metastatic Breast Cancer
Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Assess the antitumor activity of VEGF Trap, in terms of tumor response rate, in patients with metastatic breast cancer who have received =< 2 prior chemotherapy regimens for metastatic disease, including a taxane and/or anthracycline.
II. Assess the 6-month progression-free survival rate in patients treated with VEGF Trap.
SECONDARY OBJECTIVES:
I. Describe the adverse event profile (grade using the NCI CTCAE version 3.0) of VEGF Trap in these patients.
II. Describe the progression-free survival times in patients treated with VEGF Trap.
III. Describe the overall survival of patients treated with VEGF Trap. IV. Describe the duration of response in patients treated with VEGF Trap.
OUTLINE: This is a multicenter study.
Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3-6 months for up to 5 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- North Central Cancer Treatment Group
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Histologically or cytologically confirmed adenocarcinoma of the breast
- Clinical evidence of metastatic disease
No more than 2 prior chemotherapy regimens for metastatic disease
- Prior neoadjuvant or adjuvant chemotherapy allowed*
- At least 1 prior regimen (in any setting) must have included a taxane and/or an anthracycline
Measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured per RECIST criteria
No nonmeasurable disease, defined as all other lesions, including small lesions(longest diameter < 20 mm) and truly nonmeasurable lesions, including the following:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization [FISH]) must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen in either the adjuvant or metastatic setting, unless there was a contraindication
- No known CNS metastases
- No evidence of leptomeningeal involvement
- Hormone receptor status not specified
- Male or female
- Menopausal status not specified
- ECOG performance status 0-1
- Life expectancy > 3 months
- WBC ≥ 3,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 75,000/mm³
- Hemoglobin > 8.0 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3 times ULN
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN
- Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study treatment
- No significant traumatic injury within the past 4 weeks
- No history of allergy or hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, drug product excipients, or agents chemically or biologically similar to VEGF Trap
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No nonhealing wound, fracture, or ulcer
- No stage III or IV invasive, nonbreast malignancy within the past 5 years
- No history of lung carcinoma of squamous cell type
No clinically significant cardiovascular disease, including any of the following:
- Cerebrovascular accident or stroke within the past 6 months
- Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg OR systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg on ≥ 2 separate occasions within the past 3 months
- Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months
- New York Heart Association class III or IV cardiovascular disease
- Serious cardiac arrhythmia requiring medication
- Peripheral vascular disease ≥ grade 2 within the past 6 months
- Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months
- No evidence of bleeding diathesis or uncontrolled coagulopathy
- No active, unresolved infection
- No serious concurrent medical condition that would preclude study participation
- No other condition or circumstance that would preclude compliance with study requirements
- See Disease Characteristics
- Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed
- No prior bevacizumab
- More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug therapy, or immunotherapy and recovered
- More than 4 weeks since prior major surgery or open biopsy
- More than 7 days since prior core biopsy
More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only
- Prior radiotherapy to a target lesion allowed only if there has been clear progression of the lesion since radiotherapy was completed
- Prior single-dose palliative radiotherapy within the past 2 weeks allowed
- No concurrent major surgery
- No concurrent trastuzumab
Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided the following criteria are met:
- INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent participation in another investigational clinical trial
- No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents, radiotherapy, or other nonprotocol antitumor therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment (ziv-afibercept)
Patients receive VEGF Trap IV over 1 hour on day 1.
Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Patients With Confirmed Tumor Response
Tidsramme: Up to 5 years
|
Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart.
|
Up to 5 years
|
Proportion of Patients Receiving Vascular Endothelial Growth Factor (VEGF) Trap With 6-month Progression-free Survival
Tidsramme: 6 months
|
The 6-month progression free survival rate was defined as the proportion of efficacy-evaluable patients on study treatment and progression-free 6 months from registration.
Patients who died without documentation of progression will be considered to have progressed on the date of their death.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progression Free Survival
Tidsramme: Time from registration to disease progression or death (up to 5 years)
|
Progression-free survival was defined as the number of months from registration to the date of disease progression or death, with patients who died without documentation of progression being considered to have progressed on the date of their death.
|
Time from registration to disease progression or death (up to 5 years)
|
Overall Survival
Tidsramme: Time from registration to death or last follow up (up to 5 years)
|
Overall survival time was defined as the number of months from registration to the date of death or last follow-up
|
Time from registration to death or last follow up (up to 5 years)
|
Median Duration of Response
Tidsramme: Up to 5 years
|
Duration of response was defined as for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a complete response or partial response to the date progression is documented.
|
Up to 5 years
|
Number of Participant With Previous Treatment of Anti-HER2 With Cardiac Events
Tidsramme: Up to 5 years
|
Up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Edith Perez, North Central Cancer Treatment Group
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NCI-2012-01827
- U10CA025224 (U.S. NIH-stipend/kontrakt)
- NCCTG-N0537
- CDR0000491314 (Registeridentifikator: PDQ (Physician Data Query))
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metastatisk brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
I-Mab Biopharma Co. Ltd.Ikke lenger tilgjengeligSolid Tumor Metastatic Cancer Advanced Cancer
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
AmgenAktiv, ikke rekrutterendeKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, Forente stater, Canada, Belgia, Spania, Korea, Republikken, Nederland, Storbritannia, Australia, Danmark, Ungarn, Sverige, Taiwan, Hellas, Den russiske føderasjonen, Sveits, Frankrike, Italia, Japan, Polen, Brasil, Tyskland, ...
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på ziv-aflibercept
-
Regeneron PharmaceuticalsSanofiFullførtSolide svulsterForente stater, Canada
-
Shahid Beheshti University of Medical SciencesUkjentDiabetisk makulært ødemIran, den islamske republikken
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)FullførtLymfom | Uspesifisert voksen solid svulst, protokollspesifikkForente stater
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)Fullført
-
Dana-Farber Cancer InstituteFullført
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)FullførtLymfom | Uspesifisert voksen solid svulst, protokollspesifikkForente stater
-
SanofiRegeneron PharmaceuticalsFullførtNeoplasmer i eggstokkene | AscitesForente stater, Canada, Spania, India, Belgia, Østerrike, Ungarn, Israel, Storbritannia
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)Fullført
-
Rafic Hariri University HospitalUkjentSentral retinal veneokklusjon | Aldersrelatert makuladegenerasjonLibanon
-
SanofiRegeneron PharmaceuticalsFullførtNeoplasmer | Kreft i eggstokkenForente stater, Frankrike, Canada, Australia, Tyskland, Italia, Nederland, Portugal, Spania, Sverige, Sveits